Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis

Abstract Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2020-07, Vol.71 (2), p.415-418
Hauptverfasser:	Seung, Kwonjune J, Khan, Palwasha, Franke, Molly F, Ahmed, Saman, Aiylchiev, Stalbek, Alam, Manzur, Putri, Fauziah Asnely, Bastard, Mathieu, Docteur, Wisny, Gottlieb, Gary, Hewison, Catherine, Islam, Shirajul, Khachatryan, Naira, Kotrikadze, Tinatin, Khan, Uzma, Kumsa, Andargachew, Lecca, Leonid, Tassew, Yoseph Melaku, Melikyan, Nara, Naing, Ye Yint, Oyewusi, Lawrence, Rich, Michael, Wanjala, Stephen, Yedilbayev, Askar, Huerga, Helena, Mitnick, Carole D
Format:	Artikel
Sprache:	eng
Schlagworte:	Antitubercular Agents - therapeutic use Humans Mycobacterium tuberculosis Nitroimidazoles - therapeutic use Oxazoles - therapeutic use Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765.
ISSN:	1058-4838 1537-6591
DOI:	10.1093/cid/ciz1084